• search hit 3 of 11
Back to Result List

Changing R&D models in research‑based pharmaceutical companies

  • New drugs serving unmet medical needs are one of the key value drivers of research-based pharmaceutical companies. The efficiency of research and development (R&D), defined as the successful approval and launch of new medicines (output) in the rate of the monetary investments required for R&D (input), has declined since decades. We aimed to identify, analyze and describe the factors that impact the R&D efficiency. Based on publicly available information, we reviewed the R&D models of major research-based pharmaceutical companies and analyzed the key challenges and success factors of a sustainable R&D output. We calculated that the R&D efficiencies of major research-based pharmaceutical companies were in the range of USD 3.2–32.3 billion (2006–2014). As these numbers challenge the model of an innovation-driven pharmaceutical industry, we analyzed the concepts that companies are following to increase their R&D efficiencies: (A) Activities to reduce portfolio and project risk, (B) activities to reduce R&D costs, and (C) activities to increase the innovation potential. While category A comprises measures such as portfolio management and licensing, measures grouped in category B are outsourcing and risk-sharing in late-stage development. Companies made diverse steps to increase their innovation potential and open innovation, exemplified by open source, innovation centers, or crowdsourcing, plays a key role in doing so. In conclusion, research-based pharmaceutical companies need to be aware of the key factors, which impact the rate of innovation, R&D cost and probability of success. Depending on their company strategy and their R&D set-up they can opt for one of the following open innovators: knowledge creator, knowledge integrator or knowledge leverager.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Name:Schuhmacher, Alexander
URN:urn:nbn:de:bsz:rt2-opus4-8176
DOI:https://doi.org/10.1186/s12967-016-0838-4
ISSN:1479-5876
Erschienen in:Journal of translational medicine
Publisher:BioMed Central
Place of publication:London
Document Type:Article
Language:English
Year of Publication:2016
Volume:14
Pagenumber:11
First Page:1
Last Page:11
Dewey Decimal Classification:610 Medizin, Gesundheit
Open Access:Ja
Licence (German):License Logo  Creative Commons - Namensnennung